Qiagen N.V. (QGEN)
NYSE · Healthcare · Diagnostics & Research
$45.79+2.32%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $9.5B
- P/E (trailing)
- 23.2
- Forward P/E
- 17.5
- Dividend yield
- 0.8%
- 52-week range
- $32.53 – $57.82
- 52-week change
- −4.38%
- EPS (trailing)
- $1.97
- Analyst rating
- 2.3 Buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $2.1B (+5.65%)
- Net income
- $425M
- Operating margin
- 22.3%
- Diluted EPS
- $1.94
- Free cash flow
- $453M
From the company’s annual report on SEC EDGAR.
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
Headquarters: Venlo, Netherlands · 5,500 employees · qiagen.com